Heron Inc

HRTX NASDAQ
18.18
+0.45
+2.54%
After Hours: 18.18 0 0.00% 16:44 05/24 EDT
Open
17.82
Prev Close
17.73
High
18.33
Low
17.82
Volume
668.45K
Avg Vol (3M)
1.25M
52 Week High
42.90
52 Week Low
16.20
% Turnover
0.84%
Market Cap
1.44B
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
MORE >

Recently

Name
Price
%Change